Follicular Lymphoma: When Germinal Center B Cells Go Rogue

Follicular lymphoma (FL) is the most common indolent B cell lymphoma in adults and the second most common non-Hodgkin lymphoma overall. Its origin in germinal center B cells provides crucial insights into its biology and shapes therapeutic approaches.

The Hallmark Translocation

The hallmark molecular event in follicular lymphoma is the t(14;18)(q32;q21) chromosomal translocation, present in approximately 85% of cases. This translocation places the BCL2 gene under control of the immunoglobulin heavy chain enhancer, resulting in BCL2 protein overexpression. BCL2 is anti-apoptotic—its overexpression rescues germinal center B cells from programmed cell death, allowing them to accumulate and acquire additional mutations driving full malignant transformation.

Additional Genetic Alterations

The t(14;18) translocation alone is insufficient for lymphomagenesis. Additional mutations affecting epigenetic regulators are required: KMT2D (MLL2) mutated in 80-90% of FL cases; CREBBP, an acetyltransferase that impairs p53 response when mutated; EZH2 with gain-of-function mutations in ~25% of FL enhancing gene silencing; and BCL6 rearrangements affecting the master GC transcription factor.

The Tumor Microenvironment

Follicular lymphoma cells are exquisitely dependent on their microenvironment. The tumor maintains a pseudo-germinal center architecture with follicular dendritic cells and infiltrating T cells that provide crucial survival signals through CD40L, IL-4, and other factors. This microenvironmental dependence is both a vulnerability and a therapeutic opportunity.

Modern Treatment and Transformation

Treatment has been transformed by targeted therapies: rituximab (anti-CD20) is the backbone of most FL regimens; venetoclax (BCL2 inhibitor) directly targets the founding oncogenic event; tazemetostat (EZH2 inhibitor) is approved for FL with EZH2 mutations; CAR-T cell therapy is emerging for multiply relapsed disease. Histologic transformation to DLBCL occurs in approximately 2-3% of patients per year and carries significantly worse prognosis.

Read more about lymphoma biology and treatment on our blog.